Breakthrough invasive fungal infections (IFI s) have emerged as a significant problem in
patients receiving systemic antifungals; however, consensus criteria for defining …

This review compares the pharmacology, spectrum of antifungal activity, pharmacokinetic
and pharmacodynamic properties, safety and clinical efficacy of the three licensed …

Invasive fungal infections are a growing problem in critically ill patients and are associated
with increased morbidity and mortality. Most of them are due to Candida species, especially …

Traditionally, many invasive fungal infections were associated with a poor prognosis,
because effective therapeutic options were limited. The recent development of new …

The increasing emergence of antimicrobial-resistant organisms, especially methicillin-
resistant Staphylococcus aureus (MRSA), has resulted in the increased use of rifampin …

The changing pattern in fungal infections has driven the need to expand the targets of
antifungal activity. The echinocandins are the newest addition to the arsenal against fungal …

The incidence of invasive fungal infections, especially those due to Aspergillus spp. and
Candida spp., continues to increase. Despite advances in medical practice, the associated …

This article reviews in vitro metabolic and in vivo pharmacokinetic drug–drug interactions of
nine antifungal agents: six azoles (fluconazole, itraconazole, ketoconazole, miconazole …

We studied the time course for the reversal of rifampin's effect on the pharmacokinetics of
oral midazolam (a cytochrome P450 (CYP) 3A4 substrate) and digoxin (a P‐glycoprotein (P …

Antifungal agents may be associated with significant toxicity or drug interactions leading to
sub‐therapeutic antifungal drug concentrations and poorer clinical outcomes for patients …